On the afternoon of May 6th, 2016, Tianjin Minxiang Biomedical Inc. held the elaborate listing and ringing ceremony in national middle ＆ small-sized enterprises share transfer center (hereinafter referred to as "New Three Board").

        Along with a clear ring for market opening, Tianjin Minxiang Biomedical Inc. (stock short name “Minxiang Biomedical”, stock code: 834738) officially launches the new attempt in capital market.

        On the afternoon of May 6th, 2016, Tianjin Minxiang Biomedical Inc. held the elaborate listing and ringing ceremony in national middle ＆ small-sized enterprises share transfer center (hereinafter referred to as “New Three Board”). The Chairman, Liu Wanli, accompanying with senior managers and shareholder representative attended the listing ceremony and witnessed another landmark moment on the historic development of Minxiang Biomedical.

        Founded in December 2005, the predecessor of Tianjin Minxiang Biomedical Inc. is Tianjin Minxiang Biomedical Science and Technology Inc. and the company was officially listed in National Equity Exchange and Quotation (NEEQ) on December 9th, 2015.The successive listing indicated that Minxiang Biomedical formally stepped into the capital market which would promote the faster and more stable great-leap-forward development of the enterprise.

Listing ceremony is held elaborately, indicating that Minxiang Biomedical steps into great-leap-forward developing phrase.

        At present, the company possesses the world's largest production base of amantadine hydrochloride and could simultaneously provide high-quality and high-efficient products for domestic and overseas industry magnates, such as Germany's BASF, American's SACHEM and Valiant.

        With a huge market potential, adamantane, amantadine hydrochloride and other adamantanederivatives are widely used in the production of antiviral drugs and diabetes drugs. At the present stage, the company supplies medical intermediate of Statins diabetes drugs for domestic and overseas industry magnates. At the same time, the company accelerates the research and development and declaration of Statins preparations.

        Except for the application in medicine field, amantadine hydrochloride is one of the main raw materials of macromolecular polymer that can be regarded as the core in Diesel Particulate Filter (DPF).

        With the upgrading of executive standards for international automobile exhaust, the research and development and application of environmental protection materials generate into the new and huge productivity. Compared with traditional materials, macromolecular polymer contained adamantanepossesses larger adsorption efficiency and optimized integration expenses which means that they would inevitably become the important materials for exhaust disposal evolution of new generation automobiles.

        Throughout the ten-year-long development and accumulation of Minxiang Biomedical; it's believed that the enterprise is deeply subjected to the respects and acceptance of cooperative partners all the time, makes great contribution to domestic industrial development, and wins the compliments and praise from all walks of life by our substantial and rigorous scientific research strength, system-completed industrial basis and good quality series products which endows the company with unlimited market prospect.

        Guided by the leading team in which Chairman Liu Wanli is the core factor; Minxiang Biomedical would take listing on "New Three Board" as a new start, adhere to the uniform cultural concept of "Saving the Kindness and Pursuing the Confucianism", intensively aim at the two fields of medicament and chemical engineering, boost the development with scientific and technological innovation, and establish an everlasting career with professional quality and efficient services.